Lukang Pharmaceutical’s announcement on the company and its holding subsidiaries participating in the eleventh batch of national centralized drug procurement
Securities code: 600789 Securities abbreviation: Lukang Pharmaceutical Announcement number: 2025-052
Shandong Lukang Pharmaceutical Co., Ltd.
Announcement on the company and its holding subsidiaries participating in the eleventh batch of national centralized drug procurement
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Recently, the Joint Drug Procurement Office of the National Organization issued the "Notice on the Announcement of the Selection Results of the National Centralized Drug Procurement (GY-YD2025-1)". Some drugs of Shandong Lukang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and its holding subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (hereinafter referred to as the "Saite Company") were selected for this centralized procurement. The relevant information is now announced as follows:
1. Basic information about the selected product
Company Variety Representative Winning Price Supply Province Indications
Name Name Specification Category (Area) Lower respiratory tract infection and urinary tract infection caused by sensitive bacteria
injection
infection, abdominal infection, pelvic infection, sepsis,
Head 3.8 yuan/
Skin and soft tissue infections, bone and joint infections, lungs 1.0g Apoconazole branch
Meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae
Sodium oxime
inflammatory and simple gonorrhea
Shandong Shandong
For adults with type 2 diabetes:
monotherapy
Anti-drug
Can be used as monotherapy, based on diet and exercise
Shares have
improve blood sugar control.
Ltd.
combination therapy
Jiangsu and Sidage When using metformin hydrochloride alone for blood sugar control
10mg*7 2.21 yuan Sichuan, Hubei, Liejing When the condition is not good, it can be used in combination with metformin hydrochloride
Tablets/box/box Gansu and Western tablets are used to improve blood sugar control based on diet and exercise.
Tibetan system;
When using insulin alone or in combination with oral
When blood sugar is not well controlled after taking hypoglycemic drugs, pancreatic islets can be used
Combined use of vitamins, modified on the basis of diet and exercise
Good blood sugar control.
Shandong Shandong
This product is suitable for megaloblastic anemia, nutritional
Anti-drug adverse anemia, anemia during pregnancy, polyneuropathy
Adenosine 0.5mg*
Group competition Menstrual cramps, radiculitis, trigeminal neuralgia, ischium 5.76 yuan Hebei, Jiangcobalamin 48 capsules/
Specially limited neuralgia and nerve paralysis. It can also be used for nutritional / box West, Fujian capsule box
Responsible Public Diseases and Leukocytosis Caused by Radiation and Drugs
Adjuvant treatment of cytopenias.
Division
Metso Zhejiang and Shan are mainly used for acute skeletal muscle pain or discomfort.
Bamo 10mg:1 8.7 yuan/
Treatment of symptoms, such as joint muscle sprains, lumbar muscle strain, injection of g-branch
Damage, sciatica, etc.
Liquid Tibet Note:
The actual purchase quantity of the above varieties shall be subject to the final signed purchase contract.
2. The impact of this election on the company
The total sales of the above-mentioned selected products in 2024 will be 404.76 million yuan, accounting for approximately 6.49% of the company's operating income in 2024. Sales in the first half of 2025 totaled 225.2379 million yuan, accounting for approximately 7.14% of the company's operating income in the first half of 2025.
This centralized procurement is the eleventh batch of centralized bulk procurement of drugs organized by the state. In terms of implementation, medical institutions across the country give priority to the selected varieties from the centralized procurement and ensure the completion of the agreed procurement volume, which will help new products quickly enter the terminal and expand the company's coverage in related pharmaceutical fields. The profit margin of the selected products will face phased adjustments. In the future, the company will continue to improve the quality of operation and management by optimizing product structure, strengthening cost control and other measures.
3. Risk warning
There are still uncertainties in follow-up matters such as the signing of the purchase contract for the company's selected products and the implementation of market sales after mass purchase. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shandong Lukang Pharmaceutical Co., Ltd.
November 8, 2025